Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Merck cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.
This is a summary aggregated from CNBC. Read the complete article on the original site:
Read full article at CNBC
